General pharmacology studies in the pharmaceutical industry: Example of a basic program

被引:0
|
作者
Pairet, M
Diederen, W
Guth, B
Kanai, K
Mauz, A
Pieper, M
van Ryn, J
Schierok, H
Walland, A
Winquist, R
机构
[1] Boehringer Ingelheim Pharma Deutschland, Dept Biol Res Gen Pharmacol, D-88397 Biberach, Germany
[2] Nippon Boehringer Ingelheim, Kawanishi, Japan
[3] Nippon Boehringer Ingelheim, Kawanishi, Japan
[4] Boehringer Ingelheim Pharma Deutschland, Ingelheim, Germany
[5] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
关键词
methods; regulatory authorities; good laboratory practice; general pharmacology;
D O I
10.1002/(SICI)1098-2299(199710)42:2<57::AID-DDR1>3.0.CO;2-O
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The objectives of general pharmacology (GP) studies from the point of view of pharmacologists working in pharmaceutical industry are presented and compared with the requirements of regulatory authorities, using the Japanese Guidelines as an example. Based on these requirements, as well as the internal requirements of other departments involved in drug research and development, a strategy for a basic program of GP studies is suggested. This strategy involves the consideration of practical aspects, animal species, route of administration, and recommended doses. In addition, the issue of "Good Laboratory Practice" and whether this should be implemented in GP studies is discussed. In conclusion, several areas where GP studies could be improved are indicated. (C) 1997 Wiley-Liss, Inc.
引用
收藏
页码:57 / 62
页数:6
相关论文
共 50 条